India: Product Patent Regime & Pharmaceutical Industry In India - The Challenges Ahead

Last Updated: 10 January 2005
Article by Manisha Singh Nair

The Prologue

With the nearing of the TRIPS deadline, the pharmaceutical industry in India is gearing up to face new challenges. The product patent regime is no longer the challenge - it is a reality that the Indian pharma industry has accepted.

The new set of challenges stem from the deeper implications of the imminent product patent regime. With the exception of a few, most Indian pharma companies are unfamiliar with the nuances of complex patent prosecution strategies. The research-based pharmaceutical companies, on the other hand, have first hand knowledge of successfully designing and implementing, sophisticated patent prosecution strategies. Therefore, the first hurdle for the Indian pharma industry is unevenness in the domain knowledge on patents. One of the ways to overcome this is to learn the use of patents as a business tool. The unrealistic defence against the global norms on patents is perhaps the most critical post-TRIPS challenge faced by the Indian pharmaceutical industry.

This article attempts to analyze the implications of the TRIPS compliant patent regime. The key issues discussed in this article are:

  1. The scope and extent of patentability of pharmaceutical products;
  2. Evergreening – the patent term extension strategies; and
  3. Implications of Compulsory Licensing provisions

Scope and Extent of Patentability - Pharmaceutical products

Article 27 of the TRIPS Agreement harmonizes the subject matter of patent in a broad manner. However, the exclusions permitted under the TRIPS Agreement have created wide variance in the Indian Patent Act, 1970 (‘the Act’). Complying verbatim with Article 27, Section 2(1)(j) of the Act provides that ‘invention means a new product or process involving inventive step and capable of industrial application’. Section 3 of the Act explicitly excludes certain categories of inventions from the scope of patentability. Critical categories include-plants, animals, parts of plants and/or animals, seeds, essentially biological processes, mathematical or business methods, computer program per se, inventions based on traditional knowledge, methods of treatment, diagnostic, therapeutic, and surgical methods. Section 2(1)(j) and Section 3 are inextricably linked with each other; any addition in the latter would result in the constriction of the former.

While Section 3 per se poses a direct conflict with the general mandate of Article 27 of the TRIPS Agreement, some of these restrictions can in fact stay on, provided they come under the general exceptions under the TRIPS, as provided in Art. 27 (2) and (3). One needs to closely watch the dialectics of Section 2(1) (j) and Section (3) of the Act in view of the substantive provisions contained in Art. 27(1) and the exceptions to patentability provided under Article 27(2) and (3) of the TRIPS Agreement.

Patentability of Pharmaceutical & Related Inventions

A general reading of Section 2(1) (j) (which defines patentable inventions) with Section 3 of the Act (that provides the list of subject matters excluded from patentability) do not clearly indicate if it is possible to interpret these provisions to exclude certain aspects of pharmaceutical inventions from the scope of patentable subject matters. A section of the Indian pharma industry even today argues that a distinction has to be drawn between primary and secondary patents in the field of pharmaceutical inventions. According to them, primary patents are the ones directed at new molecules and secondary patents cover new combinations, optical isomers, active metabolites, polymorphs, ‘prodrugs’, new uses and so on. The question here is whether it is permissible under the TRIPS to draw such a distinction.

The Government of India seems to be adopting a balanced approach in addressing this issue. In the proposed Patent (Amendment) Bill, 2003, it is proposed to substitute the words "new use of known substance" with the words "mere new use of a known substance" in Section 3(d) of the Act. The interpretative scope of this is yet to be seen. It could eventually lead to the acceptability of ‘Swiss-type’ new use claims.

The patentability of diagnostic methods under Section 3 (i) of the Act poses another important question with respect to the possible distinction between ‘in vitro’ and ‘in vivo’ methods of diagnostics. The Patents Amendment Bill, 2003 has not introduced any distinction between ‘in vitro’ and ‘in vivo’ methods of diagnosis. While ‘in vitro’ methods of diagnosis would involve tests on samples taken from the body and performed outside the body, (like taking blood samples and testing for diagnosis of a disease like malaria), the ‘in vivo’ methods of diagnosis would include performing the methods on the human body (like CT scanning of the body). Section 3(i) of the Act provides that any process for the diagnostic or other treatment of human beings or any process for a similar treatment of animals is not patentable. In view of this, ‘in vitro’ diagnostic methods may be considered as a patentable subject matter.

The above being the position, the exact nature and scope of patentable inventions in the field of pharmaceutical arts will become clear only when the amended law is put to use, and possibly reviewed by the Courts of Law. Hopefully the textual law will acquire more clarity in the days to come when the Judges opine what it means and contains.

Patent Term Extension Strategies (referred to as ‘Evergreening of Patents’)

"Evergreening’ or what the pharmaceutical companies often refer to as ‘life cycle –management plans’ refers to patent term extension strategies. Using the intricacies of patent prosecution procedures, pharmaceutical companies develop ‘bullet proof’ patent portfolios around million dollar drug molecules. Typically, multiple patents are secured covering a variety of inventive aspects in respect of a basic invention without attracting double patenting rejections. This plurality of patents directed at divergent inventive aspects can at times lead to the extension of patent terms, provided the national patent law allows such flexibilities.

On a rough estimate, the Mail Box contains over 5000 patent applications filed under Sec. 5(2) of the Act. Therefore, these 5000 patent applications presumably contain claims directed at ‘substances capable of being used as food, medicine or drug’. The number of new drug molecules discovered in the last 5 years is roughly estimated at 40-45. That being the case, a certain section of Indian pharma industry argues that a majority of these patent applications are claiming secondary inventive aspects. Here again the basic question is, the extent to which, the patent statute can declare inventive aspects as unpatentable, while complying with the obligations under Art. 27 of the TRIPS Agreement.

According to the TRIPS Agreement, the term of protection for patent is 20 years counted from the filing date. As a patent prosecution and management strategy, ‘Evergreening’ enables patent term extension by developing a portfolio of patents around a basic invention. The child patents may be directed at any one of the various ancillary inventive aspect explained in the earlier section.

Adding new claims to a basic patent disclosure is permissible in certain jurisdictions. This is achieved by the effective use of patent prosecution routes including continuation patent application, divisional patent application, continuation-in-part patent application, and application for patent of addition. It is also possible to build on chains of priority from a basic patent disclosure to preserve novelty. The limitations or restrictions in the criteria of patentability and the exclusions of certain subject matters from the scope of patentability can impose serious limitations on patent prosecution strategies aimed at ‘Evergreening’.

A number of fundamental issues come in sharp interplay when structuring patent prosecution aimed at ‘Evergreening’. Unless the later applications disclose independent inventions (or inventive aspects), though linked to the invention disclosed in the basic application, the allowance of the later application(s) can lead to double patenting. On the other hand, inclusion of multiple inventive aspects (consequently multiple independent claims) in a single application can lead to ‘unity of invention’ issues. In India, the Patents (Amendment) Act, 2002 brought in an amendment to Section (10)(5) introducing ‘single inventive concept’. However, the Indian patent offices are yet to start allowing multiple independent claims. Consequently, dividing out applications is considered a normal patent prosecution step. As the effective date of filing of a divisional application is the same as the date of filing of the basic application, this may not contribute to patent term extension or ‘Evergreening.

In the absence of multiple prosecution avenues, where the applicant has the scope of working around various prosecution routes, the Indian Patents Act is rather rigid as to the time lines for priority, patent term and patentable subject matters. Hence, ‘Evergreening’ may not acquire serious dimensions in India.

Compulsory Licensing

In the thirty years of the working of India’s patents system, Compulsory Licensing provisions were never invoked. However, today it is the most widely debated topic in India. The Government of India and a number of other stakeholders consider Compulsory License as a statutory tool to effectively protect ‘public interest’ from possible abuse of monopoly. One step ahead, many consider that Compulsory License will ensure a level playing ground between the owners of Intellectual Property Rights and their competitors.

The Patents (Second Amendment) Bill, 1999 (which later became the Patents (Amendment) Act, 2002 brought in substantial amendments in the provisions concerning Compulsory Licenses. The Patents Act, 1970 originally contained a Chapter titled ‘Working of Patents, Compulsory Licences, Licenses of Right and Revocation’. The legislative intent behind the inclusion of Compulsory Licensing provisions was evident from Section 83 of the 1970 Act. The Section contained the general principles applicable to the working of a patent aimed at curbing the potential abuse of monopoly by the patentee. The local working of inventions to the fullest extend and on commercial scales and preventing the patentee from creating import monopolies were the two fundamental principles recognized in the original Act. The recent amendment added clauses (c) through to (g) to the original set of principles. The new principles are addressed at striking a balance of interests between the technology owners and technology users, promoting socio-economic progress by technological development, protection of public health and the Government of India’s rights in that regard prevention of unfair trade practices by abuse of monopoly rights by the patentee and the availability of the patented invention at affordable prices to the public.

The Act originally contained two important grounds for invocation of Compulsory Licenses. Any interested person could approach the Controller of Patents seeking a Compulsory License on grounds that (a) the reasonable requirements of the public with respect to the patented inventions have not been satisfied, and (b) patented invention is not available to the public at reasonable prices. The amended provision contained in Section 84 of the Act has included a third ground of ‘local working’ for seeking Compulsory Licenses. If the patented invention is not worked within the territory of India, it can be a ground to seek Compulsory License by any interested person. While explaining the meaning of ‘reasonable requirements of the public’, the law as it originally stood did contain a provision that the reasonable requirements of the public is deemed not to have been met, if for reason of the default of the patentee to manufacture in India the patented article, or not to give a license for the manufacture of the patented article the interests of the existing trade or industry is adversely affected. In addition to the above, under Section 92 (1) the Central Government can issue notification for the grant of compulsory licenses, at any time after the sealing of patent, in the case of ‘national emergency’ or ‘extreme urgency’ or ‘public non- commercial use’. The Controller of Patent is required to endeavor to ensure that the patented invention is available at the lowest price consistent with the patentees deriving reasonable advantage from their patent rights. Further, subsection (3) of the same Section provides that in circumstances of ‘national emergency’, ‘extreme urgency’ or ‘public non-commercial use’ including health crisis relating to AIDS, HIV, tuberculosis, malaria or other epidemic, the controller is not required to afford an opportunity of opposition to the patentee.

Difficulties may arise in the interpretation of the meaning and extent of the grounds on which Compulsory Licenses can be sought. . The expressions ‘National Emergency’ and ‘Extreme Urgency’ are nowhere defined though it can be safely inferred that these terms refer to situations of grave magnitude.

National emergency can take the form of ‘perceived terrorist attack using biological warfare’. For instance, in the year 2001 Canada overrode Bayer Corporation’s patent over Ciprofloxacin and ordered production of a million tablets of generic version from a Canadian company. Ciprofloxacin was stockpiled as an antidote for any attack on the nation using the deadly Anthrax

The amended provisions have in general broadened up the grounds for seeking Compulsory Licenses. Also the amendments have re-emphasized some of the basic principles behind the inclusion of Compulsory Licenses. The amendments are, therefore, a combination of policy statements and a set of substantive augmentation of the earlier provisions respecting Compulsory Licenses.

While some implications of the Compulsory Licensing provisions are direct and predictable, some others are indirect, and far less apparent. The law says that Compulsory License can be granted to any interested person if the patentee does not make the invention ‘available to the public’ at ‘reasonable prices’. What would be the nature and extent of ‘making the invention available to public’ for purposes of invoking Compulsory Licenses may lead to a contentious issue. These indirect and less apparent issues are likely to surface once the TRIPS compliant product patent regime comes into existence. Here again, the Courts of Law may play a decisive role in explaining the pith and substance of the textual law.


While the discussion in this article is confined to the above three issues that the Indian pharmaceutical companies face in the anvil of the new TRIPS compliant regime, the transition from a limited term process patent regime to the product patent regime can have several other far reaching implications. The impact of this transition will become evident in the years to come. In the meantime, the Indian pharmaceutical industry must gear up to face the challenges. Creation of a level playing ground is possible the moment the domain knowledge of patents is even among all the players in the Indian market place. To begin with, the efforts to achieve parity in knowing the rules of the game can be confined to India. But sooner or later the Indian pharmaceutical companies will have to transform into knowledge-based organizations capable of producing research-based medicine at prices affordable to the Indian people.

© Lex Orbis 2004

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.